2005, Number 5-6
<< Back Next >>
Med Crit 2005; 19 (5-6)
Efficacy of high-dose dexamethasone treatment for HELLP syndrome
Salazar EDC, Vega RBE, Valencia GO, Sánchez MM
Language: Spanish
References: 28
Page: 156-162
PDF size: 181.39 Kb.
ABSTRACT
Introduction: HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) is a systemic illness and is associated with preeclampsia or eclampsia.
Objective: To evaluate the efficacy of high-dose dexamethasone therapy for patients with HELLP syndrome.
Design: Prospective multicentric study.
Setting: ICUs of a three tertiary care hospitals of Yucatan, Mexico.
Patients: Fifty four patients with HELLP syndrome (mean age 26 + 7 yrs) were studied.
Interventions: Twenty-eight patients received high-dose dexamethasone (HDT), 0.55 mg/kg/24 hours and 26 patients a standard-dose dexamethasone (SDT), 0.35 mg/kg/24 hours.
Results: After treatment an increase of platelets at 12, 18 and 24 hours (p = 0.011) and a decrease of SGOT and SGPT (P = 0.046 and 0.036, respectively) in HDT was observed. Two HDT-patients and four SDT-patients died. The incidence of complications was low in HDT-patients (2/28) in comparison with SDT-patients (13/26). No patient had side effects related with the use of dexamethasone.
Conclusion: The use of dexamethasone is a promising option for the treatment of patients with HELLP syndrome.
REFERENCES
Geary M. The HELLP syndrome. Br J Obstet Gynecol 1997;104:887-91.
Rojas PG, Viveros RE, Kambly AA. Síndrome de HELLP. Estado Crítico. Conceptos actuales. Ginec Obst Mex 1996;64:64-72.
Sibai BM, RamadanMK, Ustan I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000-6.
Velasco MV, Navarrete HE, Cardona PJ, Madrazo NM. Mortalidad materna por preeclampsia-eclampsia en el Instituto Mexicano del Seguro Social 1987-1996. Rev Med IMSS 1997;35(6):451-6.
Rojas PG, Viveros RE, Fernández CE, Esparza JJ, Cabra ZR, Kambly AA. Síndrome de HELLP. Consecuencias severas de la enfermedad hipertensiva inducida por el embarazo. Ginec Obst Mex 1996;64:523-7.
Argueta ZM, Neir MC, Lira PJ, Ibarguengoitia F, Vázquez JM. Síndrome de HELLP. Experiencias de 7 años en el Instituto Nacional de Perinatología. Ginec Obst Mex 1995;63:217-21.
Romero AJ, Lara GA, Ramos LJ, Izquierdo PJ. Morbimortalidad materna en el síndrome de HELLP. Ginec Obst Mex 2001;69:189-93.
Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes and low platelets). Am J Obstet Gynecol 2000;183:444-8.
Tomsen TR. HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) presenting as generalized malaise. Am J ObstetGynecol 1995;172:1876-90.
Sibai BM, Ramaden MK, Radha SCh, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995;172:125-9.
Martin JN, Magann EF. Syndrome of HELLP. Current principles and recommended. Current Obstetric Medicine 1996;4:129-165.
Thiagarajah S, Bourgeois FJ, Ilarbert GM, Claude MR. Thrombocytopenia in preeclampsia: associated abnormalities and management principles. Am J Obstet Gynecol 1984;150:1-7.
Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 1999;181:304-9.
Magann EF, Martin JN. Critical care of HELLP syndrome with corticosteroids. Am J Perinatol 2000;17:417-22.
Martin JN. Prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome. Am J Obstet Gynecol 2001;184:1332-9.
Hirano T, Oka K, Nagao T. Clinical impact of glucocorticoid pharmacodynamics. In: Vincent JL, editor. Year Book of Intensive Care and Emergency Medicine. New York: Springer; 2000: 163-9.
Munk A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endcr Rev 1984;5:25-44.
O’Hara PM. HELLP syndrome: Recognition and perinatal management. Am Fam Physician 1999;60:829-39.
Magann EF, Bass D, Chauchan SP, Sullivan DL, Martin RW, Martin JN. Antepartum corticosteroids: disease stabilization in patients with syndrome of hemolysis, elevated liver enzymes and low platelet (HELLP). Am J Obstet Gynecol 1994;171:1148-53.
Magann EF, Perry KG, Meydrech EF, Harris RL, Chauhan SP, Martin JN. Post-partum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP). Am J Obstet Gynecol 1994;171:1154-7.
Vigil-De Gracia P, Garcia CE. Dexamethasone in the post-partum treatment of HELLP syndrome. Int J Gynecol Obstet 1997;59:217-21.
Martin JN, Perry KG, Blake PG, May WA, Moore A, Robinette L. Better maternal outcome are achieved with dexamethasone therapy for post-partum HELLP (hemolysis, elevated liver enzymes and thrombocytopenia) syndrome. Am J Obstet Gynecol 1997;177:1011-7.
Yalcin OT, Sener T, Hassa H, Ozalp S, Okur A. Effects of post-partum corticosteroids in patients with HELLP syndrome. Int J Gynecol Obstet 1998;61:141-8.
Martin JN, Magann EF. High-dose dexamethasone: a promising therapeutic option for HELLP. Contemporary OB/GYN 1999;44:55-63.
O’Brien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome. Am J Obstet Gynecol 2000;183:921-4.
Clennye J, Viera A. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. BMJ 2004;329:270-2.
Martin JM, Thigpen BD, Rose CH, Cushman JRN, More ABS et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003;189:830-4.
Helguera MA, Tenorio MR, Vigil DP, Gracia CE. Síndrome de HELLP. Análisis de 102 casos. Ginec Obst Mx 1996;64:528-30.